TPN-101
Phase 2Small molecule
TPN-101 is one of 7 small molecule programs targeting Aicardi-Goutières syndrome. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Aicardi-Goutières Syndrome
#DrugCompanyPhaseTrials
1Emtriva
GileadApproved
Olumiant
Eli LillyApproved
Ziagen
GSKPhase 2
Epivir
GGlaxo Dba Glaxosmithkline
Phase 2
Viread
GSKPhase 1
TPN-101
TTransposon Therapeutics, Inc.
Phase 2
JAK Inhibitor
FFred Hutchinson Cancer Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TPN-101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TTransposon Therapeutics, Inc.